Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTh2 cytokine inhibitor that attenuates IL-2, IL-5 and IL-13 production and has no effect on IFN-γ production. Acts as an immunoregulator that suppresses IgE production, eosinophil infiltration and histamine release. Exhibits antiasthmatic, anti-inflammatory and antifibrotic activity in vivo and is orally active.
M. Wt | 499.64 |
Formula | C16H26NO4S.C7H7O3S |
Storage | Store at RT |
Purity | ≥99% (HPLC) |
CAS Number | 94055-76-2 |
PubChem ID | 71773 |
InChI Key | RYVJQEZJUFRANT-UHFFFAOYSA-N |
Smiles | O=C(CC[S+](C)C)NC1=CC=C(OCC(O)COCC)C=C1.CC2=CC=C(S(=O)([O-])=O)C=C2 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
water | 49.96 | 100 | |
DMSO | 49.96 | 100 |
The following data is based on the product molecular weight 499.64. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2 mL | 10.01 mL | 20.01 mL |
5 mM | 0.4 mL | 2 mL | 4 mL |
10 mM | 0.2 mL | 1 mL | 2 mL |
50 mM | 0.04 mL | 0.2 mL | 0.4 mL |
References are publications that support the biological activity of the product.
Kurokawa et al (2001) Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo. Mediators Inflamm. 10 333 PMID: 11817674
Hsu et al (2007) The effects of suplatast tosilate (IPD-1151T) on innate immunity and antigen-presenting cells. Transpl.Immunol. 18 108 PMID: 18005853
Furonaka et al (2009) Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice. J.Pharmacol.Exp.Ther. 328 55 PMID: 18832650
If you know of a relevant reference for Suplatast tosylate, please let us know.
Keywords: Suplatast tosylate, Suplatast tosylate supplier, Th2, cytokine, synthesis, inhibitors, inhibits, antiasthmatic, TNF-α, TNF-alpha, Interleukins, Tumor, Necrosis, Factor-α, Factor-alpha, Cytokines, Cytokine, NF-κB, NF-kappaB, Signaling, Signalling, IPD1151T, IPD, 1151T, 3543, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Suplatast tosylate. Do you know of a great paper that uses Suplatast tosylate from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Suplatast tosylate and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.